You searched for "disease"
Prostate Scotland launches new research project into BPE with support from the Grand Lodge of Scotland
Prostate Scotland has launched a new two-year research project into benign prostatic enlargement (BPE), thanks to long-term funding support from The Grand Lodge of Scotland and Scottish Freemasons. The project aims to build a clearer picture of the experiences of...
Prostatic calculi and CIC
Although the clinical importance of prostate calculi has been debatable, it is a disease that can cause a plethora of symptoms and signs – sometimes in disguise. Clean intermittent catheter (CIC) is the gold standard method for bladder rehabilitation /...In conversation with Rebecca Porta
We were delighted to chat to Rebecca Porta, the new Chief Executive of The Urology Foundation (TUF) First of all, many congratulations on your recent appointment as Chief Executive of TUF; can you tell us a little bit about your...David Newman
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would write on a Scottish theme...Challenges of upper tract urothelial carcinoma
Upper tract uroepithelial carcinoma (UTUC) is a fairly common disease which traditionally had poorer outcomes compared to bladder cancer. This is due to various factors leading to delayed diagnosis and problems in risk stratification. Continuing efforts have focused on early...Testicular tumour imaging
Testicular tumours are the most common tumour in young males with a peak incidence seen between 25 and 34 years [1]. The overall incidence is slowly increasing, although the exact reasons for this are uncertain, and there is a greater...
Prostate Cancer: Clinical Case Scenarios
This is a useful book to browse through, particularly for trainees. There are 195 pages of clinical information divided into 13 chapters. It’s a slim book which is easy to pick up and read. It uses case scenarios to discuss...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...25 Years of Prostate Cancer UK
As leading men’s health charity, Prostate Cancer UK, celebrates its 25th anniversary, top researchers reflect on the huge progress in testing, treatment and support for men over the past 25 years. 25 years of beating prostate cancer together Matthew Hobbs,...Focal therapy for prostate cancer – ready for prime time?
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...Metabolic screening and stone-prevention in urolithiasis patients
The incidence and prevalence of kidney stones is increasing [1,2]. Significant recurrence rates are noted with 14% of patients experiencing a further episode at one year, 35% at five years, and 52% at 10 years [3]. Over 10% of stone...
